Abstract: Bone metastases are observed in a wide range of cancers leading to intolerable pain. While early detection can help the physicians in the decision of the type of treatment, various radiopharmaceuticals using phosphonates like 68Ga-EDTMP have been developed. In this work, due to the importance of absorbed dose, human absorbed dose of this new agent was calculated for the first time based on biodistribution data in Wild-type rats. 68Ga was obtained from 68Ge/68Ga generator with radionuclidic purity and radiochemical purity of higher than 99%. The radiolabeled complex was prepared in the optimized conditions. Radiochemical purity of the radiolabeled complex was checked by instant thin layer chromatography (ITLC) method using Whatman No. 2 paper and saline. The results indicated the radiochemical purity of higher than 99%. The radiolabelled complex was injected into the Wild-type rats and its biodistribution was studied up to 120 min. As expected, major accumulation was observed in the bone. Absorbed dose of each human organ was calculated based on biodistribution in the rats using RADAR method. Bone surface and bone marrow with 0.112 and 0.053 mSv/MBq, respectively, received the highest absorbed dose. According to these results, the radiolabeled complex is a suitable and safe option for PET bone imaging.
Abstract: In this study, the absorbed dose of human organs after injection of 177Lu-DOTATOC was studied based on the biodistribution of the complex in adenocarcinoma breast cancer bearing mice. For this purpose, the biodistribution of the radiolabelled complex was studied and compartmental modeling was applied to calculate the absorbed dose with high precision. As expected, 177Lu-DOTATOC illustrated a notable specific uptake in tumor and pancreas, organs with high level of somatostatin receptor on their surface and the effectiveness of the radio-conjugate for targeting of the breast adenocarcinoma tumors was indicated. The elicited results of modeling were the exponential equations, and those are utilized for obtaining the cumulated activity data by taking their integral. The results also exemplified that non-target absorbed-doses such as the liver, spleen and pancreas were approximately 0.008, 0.004, and 0.039, respectively. While these values were so much lower than target (tumor) absorbed-dose, it seems due to this low toxicity, this complex is a good agent for therapy.
Abstract: In this study, 177Lu-DOTATOC was prepared under optimized conditions (radiochemical purity: > 99%, radionuclidic purity: > 99%). The percentage of injected dose per gram (%ID/g) was calculated for organs up to 168 h post injection. Compartmental model was applied to mathematical description of the drug behaviour in tissue at different times. The biodistribution data showed the significant excretion of the radioactivity from the kidneys. The adrenal and pancreas, as major expression sites for somatostatin receptor (SSTR), had significant uptake. A pharmacokinetic model of 177Lu-DOTATOC was presented by compartmental analysis which demonstrates the behavior of the complex.
Abstract: Dosimetry is an indispensable and precious factor in patient treatment planning to minimize the absorbed dose in vital tissues. In this study, compartmental model was used in order to estimate the human absorbed dose of 177Lu-DOTATOC from the biodistribution data in wild type rats. For this purpose, 177Lu-DOTATOC was prepared under optimized conditions and its biodistribution was studied in male Syrian rats up to 168 h. Compartmental model was applied to mathematical description of the drug behaviour in tissue at different times. Dosimetric estimation of the complex was performed using radiation absorbed dose assessment resource (RADAR). The biodistribution data showed high accumulation in the adrenal and pancreas as the major expression sites for somatostatin receptor (SSTR). While kidneys as the major route of excretion receive 0.037 mSv/MBq, pancreas and adrenal also obtain 0.039 and 0.028 mSv/MBq. Due to the usage of this method, the points of accumulated activity data were enhanced, and further information of tissues uptake was collected that it will be followed by high (or improved) precision in dosimetric calculations.
Abstract: Despite the appropriate characteristics of 177Lu and DOTATOC, to our best knowledge, the therapeutic benefit of 177Lu-DOTATOC complex in breast cancer has not been reported until now. In this study, biodistribution of 177Lu-DOTA-TOC in mouse tumor model for evaluation of possible utilization of this complex in breast cancer treatment was investigated.177Lu was prepared with the specific activity of 2.6-3 GBq.mg-1 and radionuclidic purity higher than 99%. The radiolabeled complex was prepared in the optimized conditions with the radiochemical purity higher than 99%. The final solution was injected to the BALB/c mice with adenocarcinoma breast cancer. The biodistribution results showed major accumulation in the kidneys as the major excretion route and the somatostatin receptor-positive tissues such as pancreas compared with the other tissues. Also, significant uptake was observed in tumor even in longer time after injection. According to the results obtained in this research study, somatostatin receptors expressed in breast cancers can be targeted with DOTATOC analogues especially with 177Lu-DOTATOC as an ideal therapeutic agent.
Abstract: A clean spectrophotometric method for the determination of hafnium by using a green reagent, acidic extract of Ficus carica tree leaves is developed. In 6-M hydrochloric acid, hafnium reacts with this reagent to form a yellow product. The formed product shows maximum absorbance at 421 nm with a molar absorptivity value of 0.28 × 104 l mol⁻¹ cm⁻¹, and the method was linear in the 2-11 µg ml⁻¹ concentration range. The detection limit value was found to be 0.312 µg ml⁻¹. Except zirconium and iron, the selectivity was good, and most of the ions did not show any significant spectral interference at concentrations up to several hundred times. The proposed method was green, simple, low cost, and selective.
Abstract: The main goal of this paper was to make use of green reagents as a substitute of perilous synthetic reagents and organic solvents for spectrophotometric determination of hafnium(IV). The extracts taken from six different kinds of tree leaves including Acer negundo, Ficus carica, Cerasus avium, Chimonanthus, Salix babylonica and Pinus brutia, were applied as green reagents for the experiments. In 6-M hydrochloric acid, hafnium reacted with the reagent to form a yellow product and showed maximum absorbance at 421 nm. Among tree leaves, Chimonanthus showed satisfactory results with a molar absorptivity value of 0.61 × 104 l mol-1 cm-1 and the method was linear in the 0.3-9 µg mL -1 concentration range. The detection limit value was 0.064 µg mL-1. The proposed method was simple, low cost, clean, and selective.
Abstract: An early diagnosis of bone metastasis is very
important for making a right decision on a subsequent therapy. One
of the most important steps to be taken initially, for developing a new
radiopharmaceutical is the measurement of organ radiation exposure
dose. In this study, the dosimetric studies of a novel agent for
SPECT-imaging of the bone metastasis, 111In-(4-
{[(bis(phosphonomethyl))carbamoyl]methyl}7,10bis(carboxymethyl)
-1,4,7,10-tetraazacyclododec-1-yl) acetic acid (111In-BPAMD)
complex, have been carried out to estimate the dose in human organs
based on the data derived from mice. The radiolabeled complex was
prepared with high radiochemical purity in the optimal conditions.
Biodistribution studies of the complex was investigated in the male
Syrian mice at the selected times after injection (2, 4, 24 and 48 h).
The human absorbed dose estimation of the complex was made based
on data derived from the mice by the radiation absorbed dose
assessment resource (RADAR) method. 111In-BPAMD complex was prepared with high radiochemical
purity >95% (ITLC) and specific activities of 2.85 TBq/mmol. Total
body effective absorbed dose for 111In-BPAMD was 0.205
mSv/MBq. This value is comparable to the other 111In clinically used
complexes. The results show that the dose with respect to the critical
organs is satisfactory within the acceptable range for diagnostic
nuclear medicine procedures. Generally, 111In-BPAMD has
interesting characteristics and it can be considered as a viable agent
for SPECT-imaging of the bone metastasis in the near future.
Abstract: Abstract—[Tris (1,10-phenanthroline) lanthanum(III)]
trithiocyanate is a new compound that has shown high ability for
stopping the synthesis of DNA and also acting as a photosensitizer.
Nowadays, the radiation dose assessment resource (RADAR) method
is known as the most common method for absorbed dose calculation.
177Lu was produced by (n, gamma) reaction in a research reactor.
177Lu-PL3 was prepared in the optimized condition. The
radiochemical yield was checked by ITLC method. The
biodistribution of the complex was investigated by intravenously
injection to wild-type rats via their tail veins. In this study, the
absorbed dose of 177Lu-PL3 to human organs was estimated by
RADAR method. 177Lu was prepared with a specific activity of 2.6-3
GBq.mg-1 and radionuclide purity of 99.98 %. Final preparation of
the radiolabelled complex showed high radiochemical purity of >
99%. The results show that liver and spleen have received the highest
absorbed dose of 1.051 and 0.441 mSv/MBq, respectively. The
absorbed dose values for these two dose-limiting tissues suggest
more biological studies special in tumor-bearing animals.
Abstract: The measurement of organ radiation exposure dose is
one of the most important steps to be taken initially, for developing a
new radiopharmaceutical. In this study, the dosimetric studies of a
novel agent for SPECT-imaging of the bone metastasis, 111In-
1,4,7,10-tetraazacyclododecane-1,4,7,10 tetraethylene phosphonic
acid (111In-DOTMP) complex, have been carried out to estimate the
dose in human organs based on the data derived from rats. The
radiolabeled complex was prepared with high radiochemical purity in
the optimal conditions. Biodistribution studies of the complex was
investigated in the male Syrian rats at selected times after injection
(2, 4, 24 and 48 h). The human absorbed dose estimation of the
complex was made based on data derived from the rats by the
radiation absorbed dose assessment resource (RADAR) method.
111In-DOTMP complex was prepared with high radiochemical purity
of >99% (ITLC). Total body effective absorbed dose for 111In-
DOTMP was 0.061 mSv/MBq. This value is comparable to the other
111In clinically used complexes. The results show that the dose with
respect to the critical organs is satisfactory within the acceptable
range for diagnostic nuclear medicine procedures. Generally, 111In-
DOTMP has interesting characteristics and can be considered as a
viable agent for SPECT-imaging of the bone metastasis in the near
future.
Abstract: A multilayer passive shield composed of low-activity
lead (Pb), copper (Cu), tin (Sn) and iron (Fe) was designed and
manufactured for a coaxial HPGe detector placed at a surface
laboratory for reducing background radiation and radiation dose to
the personnel. The performance of the shield was evaluated and
efficiency curves of the detector were plotted by using of various
standard sources in different distances. Monte Carlo simulations and
a set of TLD chips were used for dose estimation in two distances of
20 and 40 cm. The results show that the shield reduced background
spectrum and the personnel dose more than 95%.